Cipla is currently trading at Rs 582.25, up by 5.65 points or 0.98% from its previous closing of Rs 576.60 on the BSE.
The scrip opened at Rs 580.05 and has touched a high and low of Rs 586.50 and Rs 580.05 respectively. So far 49350 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 704.75 on 29-Oct-2015 and a 52 week low of Rs. 458.25 on 25-May-2016.
Last one week high and low of the scrip stood at Rs 586.50 and Rs 560.00 respectively. The current market cap of the company is Rs. 46790.22 crore.
The promoters holding in the company stood at 37.47%, while Institutions and Non-Institutions held 34.54% and 27.99% respectively.
Cipla’s US subsidiary, InvaGen Pharmaceuticals has received final approval from the United States Food and Drug Administration (USFDA) to market a generic Bupropion Hydrochloride extended release tablets (XL), 150 mg and 300 mg, used for treatment of major depressive disorder. The company's tablets are generic versions of Valeant's Wellbutrin XL tablets in the same strengths. Wellbutrin XL tablets and generic equivalents had US sales of approximately $792 million for the 12 month period ending June 2016, according to IMS Health.
Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1679.85 |
| Dr. Reddys Lab | 1333.05 |
| Cipla | 1305.85 |
| Zydus Lifesciences | 947.10 |
| Lupin | 2340.20 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: